🟢 Alpha Cognition is trading 6.1% up today on Alzheimer’s drug momentum and biotech sector strength

Alpha Cognition is trading 6.1% up at $9.10 on continued optimism surrounding its Alzheimer’s franchise and a broader rally across the biotech sector.

• The advance extends a sharp two-day rally following yesterday’s 8.6% gain, fueled by Zunveyl’s commercial launch momentum and encouraging BEACON real-world study data.
• Today’s move is further supported by industry-wide tailwinds as blockbuster M&A activity and positive clinical trial results drive a broader biotech sector surge.